DarrenSSigalMD

Oncology • La Jolla, CA

Physician

Join to view full profile

Dr. Sigal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sigal's full profile

Already have an account?

Office
10710 N Torrey Pines Rd
La Jolla, CA 92037
Phone+1 858-554-5269

Fax+1 858-554-8946

Education & Training

Scripps Clinic/Scripps Green HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008
University of California Davis HealthResidency, Internal Medicine, 2002 - 2005
David Geffen School of Medicine at UCLAClass of 2002

Certifications & Licensure

CA State Medical License 2003 - 2025
IL State Medical License 2024 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia Start of enrollment: 2009 Jan 01
Withdrawn
Phase 1, Phase 2
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients Start of enrollment: 2011 Nov 01
Terminated
Phase 2
TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma Start of enrollment: 2014 Dec 01
Unknown status
Phase 1
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer Start of enrollment: 2018 Jun 04
Completed
Phase 1
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma Start of enrollment: 2019 Aug 30
Recruiting
Phase 1, Phase 2
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma Start of enrollment: 2021 Jul 28
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors.
Apostolia Maria Tsimberidou, Axel Grothey, Darren Sigal, Heinz-Josef Lenz, Howard S Hochster
Cancer Chemotherapy and Pharmacology. 2024-12-01
Protracted complete response after limited checkpoint inhibitor dosing: A case report.
Quinne Sember, Darren Sigal
Clinical Case Reports. 2023-10-01
2 citations
Do patients with metastatic pancreatic adenocarcinoma to the lung have improved survival?
Aren Ebrahimi, Jason Cham, Leah Puglisi, Melanie De Shadarevian, David J Hermel
Cancer Medicine. 2023-05-01

Lectures

Oncology Update 2013
Scripps Conference Services & CME /Scripps Translational Science Institute (STSI), San Francisco, Ca - 7/27/2013
Oncology Update 2013
Scripps Conference Services & CME /Scripps Translational Science Institute (STSI), La Jolla, Califor - 7/13/2013

Press Mentions

Abivax's Phase 1/2 Clinical Study Results of ABX196 in Liver Cancer to Be Presented on Jan. 21, at ASCO GI Cancers Symposium 2022January 18th, 2022
Magazine Covers New Liver Cancer Clinical Trial at Scripps MD AndersonDecember 20th, 2019
Novel Liver Cancer Clinical Trial to Begin at Scripps MD Anderson Cancer CenterJuly 19th, 2019
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member